Tcr2 Therapeutics Inc (NASDAQ:TCRR) – Equities research analysts at Svb Leerink lowered their Q3 2019 earnings per share estimates for Tcr2 Therapeutics in a report released on Thursday, August 8th. Svb Leerink analyst J. Chang now anticipates that the company will earn ($0.56) per share for the quarter, down from their prior estimate of ($0.55). Svb Leerink also issued estimates for Tcr2 Therapeutics’ Q4 2019 earnings at ($0.61) EPS, FY2019 earnings at ($4.71) EPS and FY2020 earnings at ($2.94) EPS.
Tcr2 Therapeutics (NASDAQ:TCRR) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.46) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.11.
NASDAQ:TCRR opened at $15.25 on Monday. Tcr2 Therapeutics has a fifty-two week low of $10.04 and a fifty-two week high of $25.47. The company has a market cap of $365.80 million and a PE ratio of -0.15. The company’s 50-day simple moving average is $14.13.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MPM Asset Management LLC bought a new stake in Tcr2 Therapeutics in the 1st quarter valued at approximately $70,607,000. Redmile Group LLC bought a new stake in Tcr2 Therapeutics in the 1st quarter valued at approximately $28,686,000. Dean Capital Investments Management LLC bought a new stake in Tcr2 Therapeutics in the 1st quarter valued at approximately $694,000. BlackRock Inc. bought a new stake in Tcr2 Therapeutics in the 2nd quarter valued at approximately $1,511,000. Finally, Parametric Portfolio Associates LLC lifted its stake in Tcr2 Therapeutics by 23.5% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 35,044 shares of the company’s stock valued at $501,000 after acquiring an additional 6,672 shares in the last quarter. Hedge funds and other institutional investors own 33.26% of the company’s stock.
About Tcr2 Therapeutics
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.
Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.